Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q2 2022 · 10-Q
Revenue$469.47K$469.47K+49.8% vs Q2 2021 Net Income-$1.96M-$1.96MN/M vs Q2 2021 EPS Diluted-$0.13-$0.13— vs Q2 2021 Gross Profit$137,972+112.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Operating Cash Flowderived-$729,457N/M Free Cash Flowderived-$737,336N/M Margins · derivedGross margin29.4%+8.7 pt vs Q2 2021
Operating margin-264.1%+195.0 pt vs Q2 2021
Net margin-417.9%−426.6 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 15, 2022 · 46 d after period end